繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 上市新药 >> Glyxambi(Empagliflozin and Linagliptin Tablets)

Glyxambi(Empagliflozin and Linagliptin Tablets)

2015-04-21 02:04:12  作者:新特药房  来源:互联网  浏览次数:409  文字大小:【】【】【
简介: 英文药名:Glyxambi(Empagliflozin and Linagliptin Tablets) 中文药名:复方恩格列净/利格列汀组合片 生产厂家:礼来与勃林格殷格翰药品介绍2型糖尿病组合药片Glyxambi是首个具有独特作用的新药获FD ...

—新型降糖药物-SGLT-2抑制剂/DPP-4抑制剂的复合制剂Glyxambi(empagliflozin+ Linagliptin)获美国FDA批准上市
2015年2月6日,美国推出糖尿病复方新药Glyxambi(恩格列净/利格列汀)复方降糖药,该药是首个双效抑制剂降糖药,由已上市药物Jardiance(empagliflozin,一种钠-葡萄糖联合转运体-2(SGLT2)抑制剂)和Trajenta(linagliptin,一种二肽基肽酶-4抑制剂(DPP-4))组成。FDA于今年2月批准Glyxambi作为每日一次的口服药物,辅助饮食和运动用于改善2型糖尿病成人患者的血糖控制。Glyxambi是一种每日一次的片剂,在每天早上服药,该药由10mg或25mg SGLT2抑制剂empagliflozin和5mgDPP-IV抑制剂linagliptin组成。Glyxambi不适用于1型糖尿病或糖尿病酮症酸中毒的治疗。
empagliflozin属于钠-葡萄糖协同转运蛋白-2(SGLT-2)抑制剂类药物,开发用于2型糖尿病成人患者的治疗。新兴的SGLT-2抑制剂类药物,已被证实能够阻断肾脏中葡萄糖的再吸收作用,将过多的葡萄糖通过尿液排泄到体外,从而达到降低血糖水平的效果,而且该降糖效果不依赖于β细胞功能和胰岛素抵抗。
linagliptin则属于二肽基肽酶-4(DPP-4)抑制剂类药物,可刺激刺激胰腺分泌更多的胰岛素,并刺激肝脏产生更少的葡萄糖。目前,linagliptin已在美国上市,品牌名为Tradjenta,作为每日一次的药物,结合饮食和运动改善2型糖尿病成人患者的血糖控制。


Glyxambi(empagliflozin/linagliptin)首个将这2种具独特作用机制的药物合并至单一片剂的复方新药,该药也是勃林格-礼来糖尿病联盟联合开发的重要产品之一。
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use GLYXAMBI safely and effectively. See full prescribing information for GLYXAMBI.
GLYXAMBI ® (empagliflozin and linagliptin) tablets, for oral use
Initial U.S. Approval: 2015
RECENT MAJOR CHANGES
Warnings and Precautions (5.3, 5.5) 12/2015
Warnings and Precautions (5.10) 8/2015
INDICATIONS AND USAGE
GLYXAMBI is a sodium-glucose co-transporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. (1)
Limitations of use:
Not for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis (1.1)
Has not been studied in patients with a history of pancreatitis (1.1)
DOSAGE AND ADMINISTRATION
The recommended dose of GLYXAMBI is 10 mg empagliflozin/5 mg linagliptin once daily, taken in the morning, with or without food (2.1)
Dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily (2.1)
Assess renal function before initiating GLYXAMBI. Do not initiate GLYXAMBI if eGFR is below 45 mL/min/1.73 m2 (2.2)
Discontinue GLYXAMBI if eGFR falls persistently below 45 mL/min/1.73 m2 (2.2)
DOSAGE FORMS AND STRENGTHS
Tablets:
10 mg empagliflozin/5 mg linagliptin
25 mg empagliflozin/5 mg linagliptin (3)
CONTRAINDICATIONS
Severe renal impairment, end-stage renal disease, or dialysis (4)
History of hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity (4)
History of serious hypersensitivity reaction to empagliflozin (4)
WARNINGS AND PRECAUTIONS
Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis. If pancreatitis is suspected, promptly discontinue GLYXAMBI. (5.1)
Hypotension: Before initiating GLYXAMBI assess and correct volume status in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy. (5.2)
Ketoacidosis: Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level. If suspected, discontinue GLYXAMBI, evaluate and treat promptly. Before initiating GLYXAMBI, consider risk factors for ketoacidosis. Patients on GLYXAMBI may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis. (5.3)
Impairment in Renal Function: Monitor renal function during therapy. More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m2. (5.4)
Urosepsis and Pyelonephritis: Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated (5.5)
Hypoglycemia: Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating GLYXAMBI. (5.6)
Genital Mycotic Infections: Monitor and treat as appropriate (5.7)
Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with linagliptin (one of the components of GLYXAMBI) including anaphylaxis, angioedema, and exfoliative skin conditions. In such cases, promptly discontinue GLYXAMBI, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. (5.8)
Increased LDL-C: Monitor and treat as appropriate (5.9)
Arthralgia: Severe and disabling arthralgia has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate. (5.10)
Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with GLYXAMBI or any other antidiabetic drug. (5.11)
ADVERSE REACTIONS
The most common adverse reactions associated with GLYXAMBI (a 5% or greater incidence) were urinary tract infections, nasopharyngitis, and upper respiratory tract infections. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257 or 1-800-459-9906 TTY, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
USE IN SPECIFIC POPULATIONS
Pregnancy: There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. (8.1)
Nursing Mothers: Discontinue GLYXAMBI or discontinue nursing (8.3)
Pediatric Patients: Safety and effectiveness of GLYXAMBI in pediatric patients have not been established. (8.4)
Geriatric Patients: Higher incidence of adverse reactions related to volume depletion and reduced renal function (5.2, 5.4, 8.5)
Renal Impairment: Higher incidence of adverse reactions related to reduced renal function (2.2, 5.4, 8.6)
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Revised: 12/2015
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
GLYXAMBI tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate [see Clinical Studies (14)].
1.1 Limitations of Use
GLYXAMBI is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
GLYXAMBI has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using GLYXAMBI [see Warnings and Precautions (5.1)].
2 DOSAGE AND ADMINISTRATION
2.1 Recommended Dosage
The recommended dose of GLYXAMBI is 10 mg empagliflozin/5 mg linagliptin once daily in the morning, taken with or without food. In patients tolerating GLYXAMBI, the dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily.
In patients with volume depletion, correcting this condition prior to initiation of GLYXAMBI is recommended [see Warnings and Precautions (5.2), Use in Specific Populations (8.5), and Patient Counseling Information (17)].
No studies have been performed specifically examining the safety and efficacy of GLYXAMBI in patients previously treated with other oral antihyperglycemic agents and switched to GLYXAMBI. Any change in therapy of type 2 diabetes should be undertaken with care and appropriate monitoring as changes in glycemic control can occur.
2.2 Patients with Renal Impairment
Assessment of renal function is recommended prior to initiation of GLYXAMBI and periodically thereafter.
GLYXAMBI should not be initiated in patients with an eGFR less than 45 mL/min/1.73 m2.
No dose adjustment is needed in patients with an eGFR greater than or equal to 45 mL/min/1.73 m2.
GLYXAMBI should be discontinued if eGFR is persistently less than 45 mL/min/1.73 m2 [see Warnings and Precautions (5.2, 5.4), and Use in Specific Populations (8.6)].
3 DOSAGE FORMS AND STRENGTHS
GLYXAMBI is a combination of empagliflozin and linagliptin. GLYXAMBI is available in the following dosage forms and strengths:
10 mg empagliflozin/5 mg linagliptin tablets are pale yellow, arc triangular, flat-faced, bevel-edged film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "10/5".
25 mg empagliflozin/5 mg linagliptin tablets are pale pink, arc triangular, flat-faced, bevel-edged film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "25/5".
4 CONTRAINDICATIONS
GLYXAMBI is contraindicated in patients with:
Severe renal impairment, end-stage renal disease, or dialysis [see Use in Specific Populations (8.6)].
A history of hypersensitivity reaction to linagliptin, such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity [see Warnings and Precautions (5.8) and Adverse Reactions (6)].
History of serious hypersensitivity reaction to empagliflozin.
5 WARNINGS AND PRECAUTIONS
5.1 Pancreatitis
There have been postmarketing reports of acute pancreatitis, including fatal pancreatitis, in patients taking linagliptin. Take careful notice of potential signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue GLYXAMBI and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using GLYXAMBI.
5.2 Hypotension
Empagliflozin causes intravascular volume contraction. Symptomatic hypotension may occur after initiating empagliflozin [see Adverse Reactions (6.1)] particularly in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Before initiating GLYXAMBI, assess for volume contraction and correct volume status if indicated. Monitor for signs and symptoms of hypotension after initiating therapy and increase monitoring in clinical situations where volume contraction is expected [see Use in Specific Populations (8.5)].
5.3 Ketoacidosis
Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization have been identified in postmarketing surveillance in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including empagliflozin. GLYXAMBI is not indicated for the treatment of patients with type 1 diabetes mellitus [see Indications and Usage (1)].
Patients treated with GLYXAMBI who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of presenting blood glucose levels, as ketoacidosis associated with GLYXAMBI may be present even if blood glucose levels are less than 250 mg/dL. If ketoacidosis is suspected, GLYXAMBI should be discontinued, patient should be evaluated, and prompt treatment should be instituted. Treatment of ketoacidosis may require insulin, fluid and carbohydrate replacement.
In many of the postmarketing reports, and particularly in patients with type 1 diabetes, the presence of ketoacidosis was not immediately recognized and institution of treatment was delayed because presenting blood glucose levels were below those typically expected for diabetic ketoacidosis (often less than 250 mg/dL). Signs and symptoms at presentation were consistent with dehydration and severe metabolic acidosis and included nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. In some but not all cases, factors predisposing to ketoacidosis such as insulin dose reduction, acute febrile illness, reduced caloric intake due to illness or surgery, pancreatic disorders suggesting insulin deficiency (e.g., type 1 diabetes, history of pancreatitis or pancreatic surgery), and alcohol abuse were identified.
Before initiating GLYXAMBI, consider factors in the patient history that may predispose to ketoacidosis including pancreatic insulin deficiency from any cause, caloric restriction, and alcohol abuse. In patients treated with GLYXAMBI consider monitoring for ketoacidosis and temporarily discontinuing GLYXAMBI in clinical situations known to predispose to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery).
5.4 Impairment in Renal Function
Empagliflozin increases serum creatinine and decreases eGFR. The risk of impaired renal function with empagliflozin is increased in elderly patients and patients with moderate renal impairment. More frequent monitoring of renal function is recommended in these patients [see Use in Specific Populations (8.5, 8.6)]. Renal function should be evaluated prior to initiating GLYXAMBI and periodically thereafter.
5.5 Urosepsis and Pyelonephritis
There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization in patients receiving SGLT2 inhibitors, including empagliflozin. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated [see Adverse Reactions (6)].
5.6 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
Insulin and insulin secretagogues are known to cause hypoglycemia. The use of empagliflozin or linagliptin in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin was associated with a higher rate of hypoglycemia compared with placebo in a clinical trial. Therefore, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia when used in combination with GLYXAMBI.
5.7 Genital Mycotic Infections
Empagliflozin increases the risk for genital mycotic infections [see Adverse Reactions (6.1)]. Patients with a history of chronic or recurrent genital mycotic infections were more likely to develop mycotic genital infections. Monitor and treat as appropriate.
5.8 Hypersensitivity Reactions
There have been postmarketing reports of serious hypersensitivity reactions in patients treated with linagliptin (one of the components of GLYXAMBI). These reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with linagliptin, with some reports occurring after the first dose. If a serious hypersensitivity reaction is suspected, discontinue GLYXAMBI, assess for other potential causes for the event, and institute alternative treatment for diabetes.
Angioedema has also been reported with other dipeptidyl peptidase-4 (DPP-4) inhibitors. Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with GLYXAMBI.
5.9 Increased Low-Density Lipoprotein Cholesterol (LDL-C)
Increases in LDL-C can occur with empagliflozin [see Adverse Reactions (6.1)]. Monitor and treat as appropriate.
5.10 Severe and Disabling Arthralgia
There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider as a possible cause for severe joint pain and discontinue drug if appropriate.
5.11 Macrovascular Outcomes
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with GLYXAMBI or any other antidiabetic drug.
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Empagliflozin and Linagliptin
The safety of concomitantly administered empagliflozin (daily dose 10 mg or 25 mg) and linagliptin (daily dose 5 mg) has been evaluated in a total of 1363 patients with type 2 diabetes treated for up to 52 weeks in active-controlled clinical trials. The most common adverse reactions with concomitant administration of empagliflozin and linagliptin based on a pooled analyses of these studies are shown in Table 1.
Table 1 Adverse Reactions Reported in ≥5% of Patients Treated with Empagliflozin and Linagliptin 

GLYXAMBI
10 mg/5 mg
n=272
GLYXAMBI
25 mg/5 mg
n=273
  n (%) n (%)
Urinary tract infectiona 34 (12.5) 31 (11.4)
Nasopharyngitis 16 (5.9) 18 (6.6)
Upper respiratory tract infection 19 (7.0) 19 (7.0)
aPredefined adverse event grouping, including, but not limited to, urinary tract infection, asymptomatic bacteriuria, cystitis
Empagliflozin
Adverse reactions that occurred in ≥2% of patients receiving empagliflozin and more commonly than in patients given placebo included (10 mg, 25 mg, and placebo): urinary tract infection (9.3%, 7.6%, and 7.6%), female genital mycotic infections (5.4%, 6.4%, and 1.5%), upper respiratory tract infection (3.1%, 4.0%, and 3.8%), increased urination (3.4%, 3.2%, and 1.0%), dyslipidemia (3.9%, 2.9%, and 3.4%), arthralgia (2.4%, 2.3%, and 2.2%), male genital mycotic infections (3.1%, 1.6%, and 0.4%), and nausea (2.3%, 1.1%, and 1.4%).
Empagliflozin causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion.
Linagliptin
Adverse reactions reported in ≥2% of patients treated with linagliptin 5 mg and more commonly than in patients treated with placebo included: nasopharyngitis (7.0% and 6.1%), diarrhea (3.3% and 3.0%), and cough (2.1% and 1.4%).
Other adverse reactions reported in clinical studies with treatment of linagliptin monotherapy were hypersensitivity (e.g., urticaria, angioedema, localized skin exfoliation, or bronchial hyperreactivity) and myalgia.
In the clinical trial program, pancreatitis was reported in 15.2 cases per 10,000 patient year exposure while being treated with linagliptin compared with 3.7 cases per 10,000 patient year exposure while being treated with comparator (placebo and active comparator, sulfonylurea). Three additional cases of pancreatitis were reported following the last administered dose of linagliptin.
Hypoglycemia
Table 2 summarizes the reports of hypoglycemia with empagliflozin and linagliptin over a treatment period of 52 weeks.
Table 2 Incidence of Overalla and Severeb Hypoglycemic Adverse Reactions 

Add-on to Metformin
(52 weeks)
GLYXAMBI
10 mg/5 mg
n=136
GLYXAMBI
25 mg/5 mg
n=137
Overall (%) 2.2% 3.6%
Severe (%) 0% 0%
aOverall hypoglycemic events: plasma or capillary glucose of less than or equal to 70 mg/dL or requiring assistance
bSevere hypoglycemic events: requiring assistance regardless of blood glucose
Laboratory Tests
Empagliflozin and Linagliptin
Changes in laboratory findings in patients treated with the combination of empagliflozin and linagliptin included increases in cholesterol and hematocrit compared to baseline.
Empagliflozin
Increase in Low-Density Lipoprotein Cholesterol (LDL-C): Dose-related increases in low-density lipoprotein cholesterol (LDL-C) were observed in patients treated with empagliflozin. LDL-C increased by 2.3%, 4.6%, and 6.5% in patients treated with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively [see Warnings and Precautions (5.9)]. The range of mean baseline LDL-C levels was 90.3 to 90.6 mg/dL across treatment groups.
Increase in Hematocrit: Median hematocrit decreased by 1.3% in placebo and increased by 2.8% in empagliflozin 10 mg and 2.8% in empagliflozin 25 mg treated patients. At the end of treatment, 0.6%, 2.7%, and 3.5% of patients with hematocrits initially within the reference range had values above the upper limit of the reference range with placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively.
Linagliptin
Changes in laboratory values that occurred more frequently in the linagliptin group and ≥1% more than in the placebo group were increases in uric acid (1.3% in the placebo group, 2.7% in the linagliptin group).
6.2 Postmarketing Experience
Additional adverse reactions have been identified during postapproval use of linagliptin and empagliflozin. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Acute pancreatitis, including fatal pancreatitis [see Indications and Usage (1.1) and Warnings and Precautions (5.1)]
Ketoacidosis [see Warnings and Precautions (5.3)]
Urosepsis and pyelonephritis [see Warnings and Precautions (5.5)]
Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions [see Warnings and Precautions (5.8)]
Severe and disabling arthralgia [see Warnings and Precautions (5.10)]
Rash
Mouth ulceration, stomatitis
7 DRUG INTERACTIONS
7.1 Drug Interactions with Empagliflozin
Diuretics
Coadministration of empagliflozin with diuretics resulted in increased urine volume and frequency of voids, which might enhance the potential for volume depletion [see Warnings and Precautions (5.2)].
Insulin or Insulin Secretagogues
Coadministration of empagliflozin with insulin or insulin secretagogues increases the risk for hypoglycemia [see Warnings and Precautions (5.6)].
Positive Urine Glucose Test
Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.
Interference with 1,5-anhydroglucitol (1,5-AG) Assay
Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.
7.2 Drug Interactions with Linagliptin
Inducers of P-glycoprotein or CYP3A4 Enzymes
Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer [see Clinical Pharmacology (12.3)].
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C
GLYXAMBI
There are no adequate and well-controlled studies in pregnant women with GLYXAMBI or its individual components. GLYXAMBI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Animal Data
The combined components administered during the period of organogenesis were not teratogenic in rats up to and including a combined dose of 700 mg/kg/day empagliflozin and 140 mg/kg/day linagliptin, which is 253 and 353 times the clinical exposure. Maternal effects were limited to dose-related reduced body weight gain and concomitant reduced food consumption in pregnant rats administered a combination of ≥300 mg/kg/day empagliflozin and 60 mg/kg/day linagliptin which is 99 and 227 times the clinical exposure. A pre- and post-natal development study was not conducted with the combined components of GLYXAMBI.
Empagliflozin
Based on results from animal studies, empagliflozin may affect renal development and maturation. In studies conducted in rats, empagliflozin crosses the placenta and reaches fetal tissues. During pregnancy, consider appropriate alternative therapies, especially during the second and third trimesters.
In pre- and postnatal development studies in pregnant rats, empagliflozin was administered from gestation day 6 through to lactation day 20 (weaning) at up to 100 mg/kg/day (approximately 16 times the 25 mg maximum clinical dose) without maternal toxicity. Reduced body weight was observed in the offspring at greater than or equal to 30 mg/kg/day (approximately 4 times the 25 mg maximum clinical dose).
Linagliptin
No functional, behavioral, or reproductive toxicity was observed in offspring of female Wistar Han rats when administered linagliptin from gestation day 6 to lactation day 21 at a dose 49 times the maximum recommended human dose, based on exposure.
Linagliptin crosses the placenta into the fetus following oral dosing in pregnant rats and rabbits.
8.3 Nursing Mothers
No studies in lactating animals have been conducted with the combined components of GLYXAMBI.
Available animal data have shown excretion of empagliflozin and linagliptin in milk. It is not known whether empagliflozin and linagliptin are excreted in human milk. Empagliflozin is secreted in the milk of lactating rats reaching levels up to 5 times higher than that in maternal plasma. Since human kidney maturation occurs in utero and during the first 2 years of life when lactational exposure may occur, there may be risk to the developing human kidney. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from empagliflozin, a decision should be made whether to discontinue nursing or to discontinue GLYXAMBI, taking into account the importance of the drug to the mother.
8.4 Pediatric Use
Safety and effectiveness of GLYXAMBI in pediatric patients under 18 years of age have not been established.
8.5 Geriatric Use
GLYXAMBI
Empagliflozin is associated with osmotic diuresis, which could affect hydration status of patients age 75 years and older.
Empagliflozin
No empagliflozin dosage change is recommended based on age [see Dosage and Administration (2)]. A total of 2721 (32%) patients treated with empagliflozin were 65 years of age and older, and 491 (6%) were 75 years of age and older. Empagliflozin is expected to have diminished efficacy in elderly patients with renal impairment [see Use in Specific Populations (8.6)]. The risk of volume depletion-related adverse reactions increased in patients who were 75 years of age and older to 2.1%, 2.3%, and 4.4% for placebo, empagliflozin 10 mg, and empagliflozin 25 mg. The risk of urinary tract infections increased in patients who were 75 years of age and older to 10.5%, 15.7%, and 15.1% in patients randomized to placebo, empagliflozin 10 mg, and empagliflozin 25 mg, respectively [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)].
Linagliptin
There were 4040 type 2 diabetes patients treated with linagliptin 5 mg from 15 clinical trials of linagliptin; 1085 (27%) were 65 years and over, while 131 (3%) were 75 years and over. Of these patients, 2566 were enrolled in 12 double-blind placebo-controlled studies; 591 (23%) were 65 years and over, while 82 (3%) were 75 years and over. No overall differences in safety or effectiveness were observed between patients 65 years and over and younger patients. Therefore, no dose adjustment is recommended in the elderly population. While clinical studies of linagliptin have not identified differences in response between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out.
8.6 Renal Impairment
Empagliflozin
The efficacy and safety of empagliflozin have not been established in patients with severe renal impairment, with ESRD, or receiving dialysis. Empagliflozin is not expected to be effective in these patient populations [see Dosage and Administration (2.2), Contraindications (4) and Warnings and Precautions (5.2, 5.4)].
The glucose lowering benefit of empagliflozin 25 mg decreased in patients with worsening renal function. The risks of renal impairment [see Warnings and Precautions (5.4)], volume depletion adverse reactions and urinary tract infection-related adverse reactions increased with worsening renal function.
8.7 Hepatic Impairment
GLYXAMBI may be used in patients with hepatic impairment [see Clinical Pharmacology (12.3)].
10 OVERDOSAGE
In the event of an overdose with GLYXAMBI, contact the Poison Control Center. Employ the usual supportive measures (e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute supportive treatment) as dictated by the patient’s clinical status. Removal of empagliflozin by hemodialysis has not been studied, and removal of linagliptin by hemodialysis or peritoneal dialysis is unlikely.
11 DESCRIPTION
GLYXAMBI tablets contain two oral antihyperglycemic drugs used in the management of type 2 diabetes: empagliflozin and linagliptin.
Empagliflozin
Empagliflozin is an orally-active inhibitor of the sodium-glucose co-transporter (SGLT2).
The chemical name of empagliflozin is D-Glucitol,1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S).
The molecular formula is C23H27ClO7 and the molecular weight is 450.91. The structural formula is:
Empagliflozin is a white to yellowish, non-hygroscopic powder. It is very slightly soluble in water, sparingly soluble in methanol, slightly soluble in ethanol and acetonitrile; soluble in 50% acetonitrile/water; and practically insoluble in toluene.
Linagliptin
Linagliptin is an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme.
The chemical name of linagliptin is 1H-Purine-2,6-dione, 8-[(3R)-3-amino-1-piperidinyl]-7-(2-butyn-1-yl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-
The molecular formula is C25H28N8O2 and the molecular weight is 472.54. The structural formula is:
Linagliptin is a white to yellowish, not or only slightly hygroscopic solid substance. It is very slightly soluble in water. Linagliptin is soluble in methanol, sparingly soluble in ethanol, very slightly soluble in isopropanol, and very slightly soluble in acetone.
GLYXAMBI
GLYXAMBI tablets for oral administration are available in two dosage strengths containing 10 mg or 25 mg empagliflozin in combination with 5 mg linagliptin. The inactive ingredients of GLYXAMBI are the following: Tablet Core: mannitol, pregelatinized starch, corn starch, copovidone, crospovidone, talc and magnesium stearate. Coating: hypromellose, mannitol, talc, titanium dioxide, polyethylene glycol and ferric oxide, yellow (10 mg/5 mg) or ferric oxide, red (25 mg/5 mg).
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
GLYXAMBI
GLYXAMBI combines 2 antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes: empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.
Empagliflozin
Sodium-glucose co-transporter 2 (SGLT2) is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Empagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Linagliptin
Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output.
12.2 Pharmacodynamics
Empagliflozin
Urinary Glucose Excretion
In patients with type 2 diabetes, urinary glucose excretion increased immediately following a dose of empagliflozin and was maintained at the end of a 4-week treatment period averaging at approximately 64 grams per day with 10 mg empagliflozin and 78 grams per day with 25 mg empagliflozin once daily.
Urinary Volume
In a 5-day study, mean 24-hour urine volume increase from baseline was 341 mL on Day 1 and 135 mL on Day 5 of empagliflozin 25 mg once daily treatment.
Cardiac Electrophysiology
In a randomized, placebo-controlled, active-comparator, crossover study, 30 healthy subjects were administered a single oral dose of empagliflozin 25 mg, empagliflozin 200 mg (8 times the maximum recommended dose), moxifloxacin, and placebo. No increase in QTc was observed with either 25 mg or 200 mg empagliflozin.
Linagliptin
Linagliptin binds to DPP-4 in a reversible manner and increases the concentrations of incretin hormones. Linagliptin glucose-dependently increases insulin secretion and lowers glucagon secretion, thus resulting in a better regulation of the glucose homeostasis. Linagliptin binds selectively to DPP-4 and selectively inhibits DPP-4, but not DPP-8 or DPP-9 activity in vitro at concentrations approximating therapeutic exposures.
Cardiac Electrophysiology
In a randomized, placebo-controlled, active-comparator, 4-way crossover study, 36 healthy subjects were administered a single oral dose of linagliptin 5 mg, linagliptin 100 mg (20 times the recommended dose), moxifloxacin, and placebo. No increase in QTc was observed with either the recommended dose of 5 mg or the 100-mg dose. At the 100-mg dose, peak linagliptin plasma concentrations were approximately 38-fold higher than the peak concentrations following a 5-mg dose.
12.3 Pharmacokinetics
GLYXAMBI
The results of the bioequivalence study in healthy subjects demonstrated that GLYXAMBI (25 mg empagliflozin/5 mg linagliptin) combination tablets are bioequivalent to coadministration of corresponding doses of empagliflozin and linagliptin as individual tablets. Administration of the fixed-dose combination with food resulted in no change in overall exposure of empagliflozin or linagliptin; however, the peak exposure was decreased 39% and 32% for empagliflozin and linagliptin, respectively. These changes are not likely to be clinically significant.
Absorption
Empagliflozin
The pharmacokinetics of empagliflozin has been characterized in healthy volunteers and patients with type 2 diabetes and no clinically relevant differences were noted between the two populations. After oral administration, peak plasma concentrations of empagliflozin were reached at 1.5 hours post-dose. Thereafter, plasma concentrations declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. The steady state mean plasma AUC and Cmax were 1870 nmol·h/L and 259 nmol/L, respectively, with 10 mg empagliflozin once daily treatment, and 4740 nmol·h/L and 687 nmol/L, respectively, with 25 mg empagliflozin once daily treatment. Systemic exposure of empagliflozin increased in a dose-proportional manner in the therapeutic dose range. The single-dose and steady-state pharmacokinetic parameters of empagliflozin were similar, suggesting linear pharmacokinetics with respect to time.
Administration of 25 mg empagliflozin after intake of a high-fat and high-calorie meal resulted in slightly lower exposure; AUC decreased by approximately 16% and Cmax decreased by approximately 37%, compared to fasted condition. The observed effect of food on empagliflozin pharmacokinetics was not considered clinically relevant and empagliflozin may be administered with or without food.
Linagliptin
The absolute bioavailability of linagliptin is approximately 30%. High-fat meal reduced Cmax by 15% and increased AUC by 4%; this effect is not clinically relevant. Linagliptin may be administered with or without food.
Distribution
Empagliflozin
The apparent steady-state volume of distribution was estimated to be 73.8 L based on a population pharmacokinetic analysis. Following administration of an oral [14C]-empagliflozin solution to healthy subjects, the red blood cell partitioning was approximately 36.8% and plasma protein binding was 86.2%.
Linagliptin
The mean apparent volume of distribution at steady state following a single intravenous dose of linagliptin 5 mg to healthy subjects is approximately 1110 L, indicating that linagliptin extensively distributes to the tissues. Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/L to 75% to 89% at ≥30 nmol/L, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin. At high concentrations, where DPP-4 is fully saturated, 70% to 80% of linagliptin remains bound to plasma proteins and 20% to 30% is unbound in plasma. Plasma binding is not altered in patients with renal or hepatic impairment.
Metabolism
Empagliflozin
No major metabolites of empagliflozin were detected in human plasma and the most abundant metabolites were three glucuronide conjugates (2-O-, 3-O-, and 6-O-glucuronide). Systemic exposure of each metabolite was less than 10% of total drug-related material. In vitro studies suggested that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9.
Linagliptin
Following oral administration, the majority (about 90%) of linagliptin is excreted unchanged, indicating that metabolism represents a minor elimination pathway. A small fraction of absorbed linagliptin is metabolized to a pharmacologically inactive metabolite, which shows a steady-state exposure of 13.3% relative to linagliptin.
Elimination
Empagliflozin
The apparent terminal elimination half-life of empagliflozin was estimated to be 12.4 h and apparent oral clearance was 10.6 L/h based on the population pharmacokinetic analysis. Following once-daily dosing, up to 22% accumulation, with respect to plasma AUC, was observed at steady-state, which was consistent with empagliflozin half-life. Following administration of an oral [14C]-empagliflozin solution to healthy subjects, approximately 95.6% of the drug-related radioactivity was eliminated in feces (41.2%) or urine (54.4%). The majority of drug-related radioactivity recovered in feces was unchanged parent drug and approximately half of drug-related radioactivity excreted in urine was unchanged parent drug.
Linagliptin
Following administration of an oral [14C]-linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated via the enterohepatic system (80%) or urine (5%) within 4 days of dosing. Renal clearance at steady state was approximately 70 mL/min.
Specific Populations
Renal Impairment
GLYXAMBI: Studies characterizing the pharmacokinetics of empagliflozin and linagliptin after administration of GLYXAMBI in renally impaired patients have not been performed [see Dosage and Administration (2.2)].
Empagliflozin: In patients with mild (eGFR: 60 to less than 90 mL/min/1.73 m2), moderate (eGFR: 30 to less than 60 mL/min/1.73 m2), and severe (eGFR: less than 30 mL/min/1.73 m2) renal impairment and subjects with kidney failure/end stage renal disease (ESRD) patients, AUC of empagliflozin increased by approximately 18%, 20%, 66%, and 48%, respectively, compared to subjects with normal renal function. Peak plasma levels of empagliflozin were similar in subjects with moderate renal impairment and kidney failure/ESRD compared to patients with normal renal function. Peak plasma levels of empagliflozin were roughly 20% higher in subjects with mild and severe renal impairment as compared to subjects with normal renal function. Population pharmacokinetic analysis showed that the apparent oral clearance of empagliflozin decreased, with a decrease in eGFR leading to an increase in drug exposure. However, the fraction of empagliflozin that was excreted unchanged in urine, and urinary glucose excretion, declined with decrease in eGFR.
Linagliptin: An open-label pharmacokinetic study evaluated the pharmacokinetics of linagliptin 5 mg in male and female patients with varying degrees of chronic renal impairment. The study included 6 healthy subjects with normal renal function (creatinine clearance [CrCl] ≥80 mL/min), 6 patients with mild renal impairment (CrCl 50 to <80 mL/min), 6 patients with moderate renal impairment (CrCl 30 to <50 mL/min), 10 patients with type 2 diabetes and severe renal impairment (CrCl <30 mL/min), and 11 patients with type 2 diabetes and normal renal function. Creatinine clearance was measured by 24-hour urinary creatinine clearance measurements or estimated from serum creatinine based on the Cockcroft-Gault formula.
Under steady-state conditions, linagliptin exposure in patients with mild renal impairment was comparable to healthy subjects.
In patients with moderate renal impairment under steady-state conditions, mean exposure of linagliptin increased (AUCτ,ss by 71% and Cmax by 46%) compared with healthy subjects. This increase was not associated with a prolonged accumulation half-life, terminal half-life, or an increased accumulation factor. Renal excretion of linagliptin was below 5% of the administered dose and was not affected by decreased renal function. Patients with type 2 diabetes and severe renal impairment showed steady-state exposure approximately 40% higher than that of patients with type 2 diabetes and normal renal function (increase in AUCτ,ss by 42% and Cmax by 35%). For both type 2 diabetes groups, renal excretion was below 7% of the administered dose.
These findings were further supported by the results of population pharmacokinetic analyses.
Hepatic Impairment
GLYXAMBI: Studies characterizing the pharmacokinetics of empagliflozin and linagliptin after administration of GLYXAMBI in hepatically impaired patients have not been performed.
Empagliflozin: In subjects with mild, moderate, and severe hepatic impairment according to the Child-Pugh classification, AUC of empagliflozin increased by approximately 23%, 47%, and 75% and Cmax increased by approximately 4%, 23%, and 48%, respectively, compared to subjects with normal hepatic function.
Linagliptin: In patients with mild hepatic impairment (Child-Pugh class A) steady-state exposure (AUCτ,ss) of linagliptin was approximately 25% lower and Cmax,ss was approximately 36% lower than in healthy subjects. In patients with moderate hepatic impairment (Child-Pugh class B), AUCss of linagliptin was about 14% lower and Cmax,ss was approximately 8% lower than in healthy subjects. Patients with severe hepatic impairment (Child-Pugh class C) had comparable exposure of linagliptin in terms of AUC0-24 and approximately 23% lower Cmax compared with healthy subjects. Reductions in the pharmacokinetic parameters seen in patients with hepatic impairment did not result in reductions in DPP-4 inhibition.
Effects of Age, Body Mass Index, Gender, and Race
Empagliflozin: Based on the population PK analysis, age, body mass index (BMI), gender and race (Asians versus primarily Whites) do not have a clinically meaningful effect on pharmacokinetics of empagliflozin [see Use in Specific Populations (8.5)].
Linagliptin: Based on the population PK analysis, age, body mass index (BMI), gender and race do not have a clinically meaningful effect on pharmacokinetics of linagliptin [see Use in Specific Populations (8.5)].
Pediatric
Studies characterizing the pharmacokinetics of empagliflozin or linagliptin after administration of GLYXAMBI in pediatric patients have not been performed.
Drug Interactions
Pharmacokinetic drug interaction studies with GLYXAMBI have not been performed; however, such studies have been conducted with the individual components of GLYXAMBI (empagliflozin and linagliptin).
Empagliflozin
In vitro Assessment of Drug Interactions
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. Empagliflozin also does not inhibit UGT1A1. Therefore, no effect of empagliflozin is anticipated on concomitantly administered drugs that are substrates of the major CYP450 isoforms or UGT1A1. The effect of UGT induction (e.g., induction by rifampicin or any other UGT enzyme inducer) on empagliflozin exposure has not been evaluated.
Empagliflozin is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but it does not inhibit these efflux transporters at therapeutic doses. Based on in vitro studies, empagliflozin is considered unlikely to cause interactions with drugs that are P-gp substrates. Empagliflozin is a substrate of the human uptake transporters OAT3, OATP1B1, and OATP1B3, but not OAT1 and OCT2. Empagliflozin does not inhibit any of these human uptake transporters at clinically relevant plasma concentrations and, therefore, no effect of empagliflozin is anticipated on concomitantly administered drugs that are substrates of these uptake transporters.
In vivo Assessment of Drug Interactions
No dose adjustment of empagliflozin is recommended when coadministered with commonly prescribed medicinal products based on results of the described pharmacokinetic studies. Empagliflozin pharmacokinetics were similar with and without coadministration of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, hydrochlorothiazide, and torasemide in healthy volunteers (see Figure 1). The observed increases in overall exposure (AUC) of empagliflozin following coadministration with gemfibrozil, rifampicin, or probenecid are not clinically relevant. In subjects with normal renal function, coadministration of empagliflozin with probenecid resulted in a 30% decrease in the fraction of empagliflozin excreted in urine without any effect on 24-hour urinary glucose excretion. The relevance of this observation to patients with renal impairment is unknown.
Figure 1 Effect of Various Medications on the Pharmacokinetics of Empagliflozin as Displayed as 90% Confidence Interval of Geometric Mean AUC and Cmax Ratios [reference lines indicate 100% (80% - 125%)]

aempagliflozin, 50 mg, once daily; bempagliflozin, 25 mg, single dose; cempagliflozin, 25 mg, once daily; dempagliflozin, 10 mg, single dose
Empagliflozin had no clinically relevant effect on the pharmacokinetics of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, digoxin, ramipril, simvastatin, hydrochlorothiazide, torasemide, and oral contraceptives when coadministered in healthy volunteers (see Figure 2).
Figure 2 Effect of Empagliflozin on the Pharmacokinetics of Various Medications as Displayed as 90% Confidence Interval of Geometric Mean AUC and Cmax Ratios [reference lines indicate 100% (80% - 125%)]
aempagliflozin, 50 mg, once daily; bempagliflozin, 25 mg, once daily; cempagliflozin, 25 mg, single dose; dadministered as simvastatin; eadministered as warfarin racemic mixture; fadministered as Microgynon®; gadministered as ramipril
Linagliptin
In vitro Assessment of Drug Interactions
Linagliptin is a weak to moderate inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes and is not an inducer of CYP isozymes, including CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 4A11.
Linagliptin is a P-glycoprotein (P-gp) substrate, and inhibits P-gp mediated transport of digoxin at high concentrations. Based on these results and in vivo drug interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates at therapeutic concentrations.
In vivo Assessment of Drug Interactions
Strong inducers of CYP3A4 or P-gp (e.g., rifampin) decrease exposure to linagliptin to subtherapeutic and likely ineffective concentrations. For patients requiring use of such drugs, an alternative to linagliptin is strongly recommended. In vivo studies indicated evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-gp and organic cationic transporter (OCT). No dose adjustment of linagliptin is recommended based on results of the described pharmacokinetic studies.
Table 3 Effect of Coadministered Drugs on Systemic Exposure of Linagliptin 

Coadministered Drug Dosing of Coadministered Druga Dosing of Linagliptina Geometric Mean Ratio
(ratio with/without coadministered drug)
No effect = 1.0
AUCc Cmax
No dosing adjustments required for linagliptin when given with the following coadministered drugs:

Metformin

850 mg TID

10 mg QD

1.20

1.03

Glyburide

1.75 mgb

5 mg QD

1.02

1.01

Pioglitazone

45 mg QD

10 mg QD

1.13

1.07

Ritonavir

200 mg BID

5 mgb

2.01

2.96

The efficacy of linagliptin may be reduced when administered in combination with strong inducers of CYP3A4 or P-gp (e.g., rifampin). Use of alternative treatments is strongly recommended [see Drug Interactions (7.2)].

Rifampin

600 mg QD

5 mg QD

0.60

0.56

aMultiple dose (steady state) unless otherwise noted
bSingle dose
cAUC = AUC(0 to 24 hours) for single dose treatments and AUC = AUC(TAU) for multiple dose treatments
QD = once daily
BID = twice daily
TID = three times daily
Table 4 Effect of Linagliptin on Systemic Exposure of Coadministered Drugs

Coadministered Drug

Dosing of Coadministered Druga

Dosing of Linagliptina

Geometric Mean Ratio
(ratio with/without coadministered drug)
No effect = 1.0

 

AUCc

Cmax

No dosing adjustments required for the following coadministered drugs:

Metformin

850 mg TID

10 mg QD

metformin

1.01

0.89

Glyburide

1.75 mgb

5 mg QD

glyburide

0.86

0.86

Pioglitazone

45 mg QD

10 mg QD

pioglitazone

metabolite M-III

metabolite M-IV

0.94

0.98

1.04

0.86

0.96

1.05

Digoxin

0.25 mg QD

5 mg QD

digoxin

1.02

0.94

Simvastatin

40 mg QD

10 mg QD

simvastatin
simvastatin acid

1.34

1.33

1.10

1.21

Warfarin

10 mgb

5 mg QD

R-warfarin

S-warfarin

INR

PT

0.99

1.03

0.93d

1.03d

1.00

1.01

1.04d

1.15d

Ethinylestradiol and levonorgestrel

ethinylestradiol 0.03 mg and levonorgestrel 0.150 mg QD

5 mg QD

ethinylestradiol

levonorgestrel

1.01

1.09

1.08

1.13

aMultiple dose (steady state) unless otherwise noted
bSingle dose
cAUC = AUC(INF) for single dose treatments and AUC = AUC(TAU) for multiple dose treatments
dAUC=AUC(0-168) and Cmax=Emax for pharmacodynamic end points
INR = International Normalized Ratio
PT = Prothrombin Time
QD = once daily
TID = three times daily
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
GLYXAMBI
No animal studies have been conducted with the combination of empagliflozin and linagliptin to evaluate carcinogenesis, mutagenesis, or impairment of fertility. General toxicity studies in rats up to 13 weeks were performed with the combined components. These studies indicated that no additive toxicity is caused by the combination of empagliflozin and linagliptin.
Empagliflozin
Carcinogenesis was evaluated in 2-year studies conducted in CD-1 mice and Wistar rats. Empagliflozin did not increase the incidence of tumors in female rats dosed at 100, 300, or 700 mg/kg/day (up to 72 times the exposure from the maximum clinical dose of 25 mg). In male rats, hemangiomas of the mesenteric lymph node were increased significantly at 700 mg/kg/day or approximately 42 times the exposure from a 25 mg clinical dose. Empagliflozin did not increase the incidence of tumors in female mice dosed at 100, 300, or 1000 mg/kg/day (up to 62 times the exposure from a 25 mg clinical dose). Renal tubule adenomas and carcinomas were observed in male mice at 1000 mg/kg/day, which is approximately 45 times the exposure of the maximum clinical dose of 25 mg.
Empagliflozin was not mutagenic or clastogenic with or without metabolic activation in the in vitro Ames bacterial mutagenicity assay, the in vitro L5178Y tk+/- mouse lymphoma cell assay, and an in vivo micronucleus assay in rats.
Empagliflozin had no effects on mating, fertility or early embryonic development in treated male or female rats up to the high dose of 700 mg/kg/day (approximately 155 times the 25 mg clinical dose in males and females, respectively).
Linagliptin
Linagliptin did not increase the incidence of tumors in male and female rats in a 2-year study at doses of 6, 18, and 60 mg/kg. The highest dose of 60 mg/kg is approximately 418 times the clinical dose of 5 mg/day based on AUC exposure. Linagliptin did not increase the incidence of tumors in mice in a 2-year study at doses up to 80 mg/kg (males) and 25 mg/kg (females), or approximately 35- and 270-times the clinical dose based on AUC exposure. Higher doses of linagliptin in female mice (80 mg/kg) increased the incidence of lymphoma at approximately 215-times the clinical dose based on AUC exposure.
Linagliptin was not mutagenic or clastogenic with or without metabolic activation in the Ames bacterial mutagenicity assay, a chromosomal aberration test in human lymphocytes, and an in vivo micronucleus assay.
In fertility studies in rats, linagliptin had no adverse effects on early embryonic development, mating, fertility, or bearing live young up to the highest dose of 240 mg/kg (approximately 943-times the clinical dose based on AUC exposure).
14 CLINICAL STUDIES
Add-on Combination Therapy with Metformin
A total of 686 patients with type 2 diabetes participated in a double-blind, active-controlled study to evaluate the efficacy and safety of empagliflozin 10 mg or 25 mg in combination with linagliptin 5 mg compared to the individual components.
Patients with type 2 diabetes inadequately controlled on at least 1500 mg of metformin per day entered a single-blind placebo run-in period for 2 weeks. At the end of the run-in period, patients who remained inadequately controlled and had an HbA1c between 7 and 10.5% were randomized 1:1:1:1:1 to one of 5 active-treatment arms of empagliflozin 10 mg or 25 mg, linagliptin 5 mg, or linagliptin 5 mg in combination with 10 mg or 25 mg empagliflozin as a fixed dose combination tablet.
At Week 24, empagliflozin 10 mg or 25 mg used in combination with linagliptin 5 mg provided statistically significant improvement in HbA1c (p-value <0.0001) and FPG (p-value <0.001) compared to the individual components in patients who had been inadequately controlled on metformin (see Table 5, Figure 3). Treatment with GLYXAMBI 25 mg/5 mg or GLYXAMBI 10 mg/5 mg daily also resulted in a statistically significant reduction in body weight compared to linagliptin 5 mg (p-value <0.0001). There was no statistically significant difference compared to empagliflozin alone.
Table 5 Glycemic Parameters at 24 Weeks in a Study Comparing GLYXAMBI to the Individual Components as Add-on Therapy in Patients Inadequately Controlled on Metformin 

GLYXAMBI
10 mg/5 mg
GLYXAMBI
25 mg/5 mg
Empagliflozin
10 mg
Empagliflozin
25 mg
Linagliptin
5 mg
HbA1c (%)          
  Number of patients n=135 n=133 n=137 n=139 n=128
  Baseline (mean) 8.0 7.9 8.0 8.0 8.0
  Change from baseline (adjusted mean) -1.1 -1.2 -0.7 -0.6 -0.7
  Comparison vs empagliflozin 25 mg or 10 mg (adjusted mean) (95% CI)a -0.4 (-0.6, -0.2)d -0.6 (-0.7, -0.4)d -- -- --
  Comparison vs linagliptin 5 mg (adjusted mean) (95% CI)a -0.4 (-0.6, -0.2)d -0.5 (-0.7, -0.3)d -- -- --
  Patients [n (%)] achieving HbA1c <7%b 74 (58) 76 (62) 35 (28) 43 (33) 43 (36)
FPG (mg/dL)          
  Number of patients n=133 n=131 n=136 n=137 n=125
  Baseline (mean) 157 155 162 160 156
  Change from baseline (adjusted mean) -33 -36 -21 -21 -13
  Comparison vs empagliflozin 25 mg or 10 mg (adjusted mean) (95% CI)a -12 (-18, -5)d -15 (-22, -9)d -- -- --
  Comparison vs linagliptin 5 mg (adjusted mean) (95% CI)a -20 (-27, -13)d -23 (-29, -16)d -- -- --
Body Weight          
  Number of patients n=135 n=134 n=137 n=140 n=128
  Baseline (mean) in kg 87 85 86 88 85
  % change from baseline (adjusted mean) -3.1 -3.4 -3.0 -3.5 -0.7
  Comparison vs empagliflozin 25 mg or 10 mg (adjusted mean) (95% CI)c 0.0 (-0.9, 0.8) 0.1 (-0.8, 0.9) -- -- --
  Comparison vs linagliptin 5 mg (adjusted mean) (95% CI)c -2.4 (-3.3, -1.5)d -2.7 (-3.6, -1.8)d -- -- --
aFull analysis population (observed case) using MMRM. MMRM model included treatment, renal function, region, visit, visit by treatment interaction, and baseline HbA1c.
bPatients with HbA1c above 7% at baseline: GLYXAMBI 25 mg/5 mg, n=123; GLYXAMBI 10 mg/5 mg, n=128; empagliflozin 25 mg, n=132; empagliflozin 10 mg, n=125; linagliptin 5 mg, n=119. Non-completers were considered failures (NCF).
cFull analysis population using last observation carried forward. ANCOVA model included treatment, renal function, region, baseline weight, and baseline HbA1c.
dp<0.001 for FPG; p<0.0001 for HbA1c and body weight
Figure 3 Adjusted Mean HbA1c Change at Each Time Point (Completers) and at Week 24 (mITT population)
16 HOW SUPPLIED/STORAGE AND HANDLING
GLYXAMBI (empagliflozin and linagliptin) tablets are available in 10 mg/5 mg and 25 mg/5 mg strengths as follows:
10 mg/5 mg tablets: pale yellow, arc triangular, flat-faced, bevel-edged, film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "10/5".
Bottles of 30 (NDC 0597-0182-30)
Bottles of 90 (NDC 0597-0182-90)
Bottles of 1000 (NDC 0597-0182-10)
Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0182-39), institutional pack.
25 mg/5 mg tablets: pale pink, arc triangular, flat-faced, bevel-edged, film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "25/5".
Bottles of 30 (NDC 0597-0164-30)
Bottles of 90 (NDC 0597-0164-90)
Bottles of 1000 (NDC 0597-0164-10)
Cartons containing 3 blister cards of 10 tablets each (3 x 10) (NDC 0597-0164-39), institutional pack.
If repackaging is required, dispense in a tight container as defined in USP.
Storage
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Store in a safe place out of reach of children.
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Instructions
Instruct patients to read the Medication Guide before starting GLYXAMBI therapy and to reread it each time the prescription is renewed. Instruct patients to inform their doctor or pharmacist if they develop any unusual symptom, or if any known symptom persists or worsens.
Inform patients of the potential risks and benefits of GLYXAMBI and of alternative modes of therapy. Also, inform patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and HbA1c testing, recognition and management of hypoglycemia and hyperglycemia, and assessment for diabetes complications. Advise patients to seek medical advice promptly during periods of stress such as fever, trauma, infection, or surgery, as medication requirements may change.
Instruct patients to take GLYXAMBI only as prescribed. If a dose is missed, it should be taken as soon as the patient remembers. Advise patients not to double their next dose.
Inform female patients of child bearing age that the use of GLYXAMBI during pregnancy has not been studied in humans, and that GLYXAMBI should only be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Based on animal data, empagliflozin may cause fetal harm in the second and third trimesters. Instruct patients to report pregnancies to their physicians as soon as possible.
Inform nursing mothers to discontinue GLYXAMBI or nursing, taking into account the importance of the drug to the mother. It is not known if empagliflozin or linagliptin is excreted in breast milk; however, based on animal data, empagliflozin may cause harm to nursing infants.
Pancreatitis
Inform patients that acute pancreatitis has been reported during postmarketing use of linagliptin. Inform patients that persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting, is the hallmark symptom of acute pancreatitis. Instruct patients to discontinue GLYXAMBI promptly and contact their physician if persistent severe abdominal pain occurs [see Warnings and Precautions (5.1)].
Hypoglycemia
Inform patients that the incidence of hypoglycemia is increased when empagliflozin, linagliptin, or GLYXAMBI is added to a sulfonylurea or insulin and that a lower dose of the sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.
Hypersensitivity Reactions
Inform patients that serious allergic reactions, such as anaphylaxis, angioedema, and exfoliative skin conditions, have been reported during postmarketing use of linagliptin (one of the components of GLYXAMBI). If symptoms of allergic reactions (such as rash, skin flaking or peeling, urticaria, swelling of the skin, or swelling of the face, lips, tongue, and throat that may cause difficulty in breathing or swallowing) occur, patients must stop taking GLYXAMBI and seek medical advice promptly.
Hypotension
Inform patients that hypotension may occur with GLYXAMBI and advise them to contact their healthcare provider if they experience such symptoms [see Warnings and Precautions (5.2)]. Inform patients that dehydration may increase the risk for hypotension, and to have adequate fluid intake.
Ketoacidosis
Inform patients that ketoacidosis has been reported during use of empagliflozin. Instruct patients to check ketones (when possible) if symptoms consistent with ketoacidosis occur even if blood glucose is not elevated. If symptoms of ketoacidosis (including nausea, vomiting, abdominal pain, tiredness, and labored breathing) occur, instruct patients to discontinue GLYXAMBI and seek medical advice immediately [see Warnings and Precautions (5.3)].
Serious Urinary Tract Infections
Inform patients of the potential for urinary tract infections, which may be serious. Provide them with information on the symptoms of urinary tract infections. Advise them to seek medical advice if such symptoms occur [see Warnings and Precautions (5.5)].
Genital Mycotic Infections in Females (e.g., Vulvovaginitis)
Inform female patients that vaginal yeast infections may occur and provide them with information on the signs and symptoms of vaginal yeast infections. Advise them of treatment options and when to seek medical advice [see Warnings and Precautions (5.7)].
Genital Mycotic Infections in Males (e.g., Balanitis or Balanoposthitis)
Inform male patients that yeast infection of penis (e.g., balanitis or balanoposthitis) may occur, especially in uncircumcised males and patients with chronic and recurrent infections. Provide them with information on the signs and symptoms of balanitis and balanoposthitis (rash or redness of the glans or foreskin of the penis). Advise them of treatment options and when to seek medical advice [see Warnings and Precautions (5.7)].
Severe and Disabling Arthralgia
Inform patients that severe and disabling joint pain may occur with this class of drugs. The time to onset of symptoms can range from one day to years. Instruct patients to seek medical advice if severe joint pain occurs [see Warnings and Precautions (5.9)].
Laboratory Tests
Inform patients that renal function should be assessed prior to initiation of GLYXAMBI and monitored periodically thereafter.
Inform patients that elevated glucose in urinalysis is expected when taking GLYXAMBI.
Inform patients that response to all diabetic therapies should be monitored by periodic measurements of blood glucose and HbA1c levels, with a goal of decreasing these levels toward the normal range. Hemoglobin A1c is especially useful for evaluating long-term glycemic control.
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ddbab689-f76c-488c-9613-4168d41dd730
2型糖尿病药物Glyxambi(empagliflozin+Linagliptin)获FDA批准首个DPP-4和SGLT-2抑制剂组合
2月2日,美国FDA批准了钠葡萄糖协同转运蛋白2(SGLT2)抑制剂empagliflozin和二肽基肽酶-4(DPP-4)抑制剂利拉利汀(Linagliptin)两个固定剂量的复方组合(商品名:Glyxambi),用于结合饮食和运动控制2型糖尿病成人患者的血糖水平。这个复方片剂含有10或25毫克的empagliflozin以及5毫克的利拉利汀。在一个有677名2型糖尿病患者参与的3期临床实验中,这些成人患者之前虽然服用高剂量的二甲双胍(每日至少1500毫克)但基线血红蛋白A1c(HbA1c)水平仍然高于7.0%,每日一次连续24周配给含有10毫克或25毫克empagliflozin的Glyxambi复方片,和empagliflozin或利拉利汀单独用药组相比,血红蛋白A1c或空腹血糖水平改善的幅度明显提高。最常见不良事件包括尿路感染(11.4%-12.5%)、鼻咽炎、和上呼吸道感染。Glyxambi由勃林格殷格翰和礼来共同开发,是第一个也是唯一的一个获得FDA批准的DPP-4抑制剂和SGLT-2抑制剂的复方组合。
药源解析
全球大约有3.87亿糖尿病患者,其中美国2900万,中国1.14亿。二甲双胍是最常用的一线口服药物,但大约有一半患者使用最高剂量的二甲双胍还不能把血糖维持在正常水平。对这些患者,GLP-1受体激动剂、DPP-4抑制剂和SGLT-2抑制剂等新型降糖药已经成为多个“治疗指南”推荐的二线药物。
GLP-1受体激动剂能提高葡萄糖依赖性的胰岛素分泌并降低餐后胰高血糖素分泌。DPP4水解GLP,所以抑制DPP4可以延长GLP的半衰期,取得降糖效果。钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂阻断肾脏葡萄糖的重吸收因此增加尿液中血糖的排泄。多个大型临床实验表明,这些新的降糖机制不仅能有效地控制2型糖尿病患者的血糖水平,GLP-1受体激动剂和SGLT2抑制剂还能在一定程度上降低患者的体重,起到减肥作用。GLP-1、DPP4、和SGLT2因此也成为药厂追逐的优质靶点,相应地市场竞争也异常激烈。比如全球上市的DPP-4抑制剂就有7个,分别是Sitagliptin、Vildagliptin、Saxagliptin、Alogliptin、Linagliptin、Gemigliptin、和Teneligliptin。
GLP-1受体激动剂、DPP-4抑制剂和SGLT-2抑制剂这些新型降糖药物都能和二甲双胍联合使用,并显示更好的疗效。所以开发和二甲双胍固定剂量的复方制剂作为2型糖尿病的一线用药也是这些厂家扩展市场的重要策略。实际上,大多数开发DPP-4抑制剂的厂家随后也申报和二甲双胍的复方制剂。除此之外,理论上这些新型降糖机制互相之间的复方甚至三方组合也可能产生更好的降糖效果。Empagliflozin和Linagliptin固定剂量的复方组合是第一个也是唯一一个获得FDA批准的SGLT-2抑制剂和DPP-4抑制剂的复方组合。

责任编辑:admin


相关文章
CANALIA COMBINATION TABLETS(氢溴酸替格列汀混合片,カナリア配合錠)
Venclyxto Filmtabletten(Venetoclax)
Synjardy XR(empagliflozin/metformin hydrochloride extended-release)tablets
2型糖尿病新复方缓释片Synjardy XR获美国FDA批准
恩格列净片|Jardiance(Empagliflozin Tablets)
2型糖尿病组合疗法Bydureon/Forxiga临床显著降低血糖
EquMet Combination Tablets LD/HD(维达列汀/盐酸二甲双胍组合片)
Janumet Filmtabl(Sitagliptin/Metformin Tablets)
KOMBIGLYZE XR Filmtabl(复方沙格列汀/盐酸二甲双胍缓释片)
Zafatek(Trelagliptin succinate Tablets)
每周服用一次的重磅糖尿病新药Marizev获日本批准
 

最新文章

更多

· 艾地苯醌薄膜包衣片|Rax...
· BAVENCIO(avelumab inje...
· SILIQ(brodalumab)单剂...
· Emflaza(deflazacort t...
· SOLIQUA 100/33(insulin...
· YOSPRALA(aspirin/omepr...
· VIEKIRA XR TABLET(das...
· Xiidra(Lifitegrast Oph...
· LARTRUVO(olaratumab in...
· EXONDYS 51(eteplirsen ...

推荐文章

更多

· 艾地苯醌薄膜包衣片|Rax...
· BAVENCIO(avelumab inje...
· SILIQ(brodalumab)单剂...
· Emflaza(deflazacort t...
· SOLIQUA 100/33(insulin...
· YOSPRALA(aspirin/omepr...
· VIEKIRA XR TABLET(das...
· Xiidra(Lifitegrast Oph...
· LARTRUVO(olaratumab in...
· EXONDYS 51(eteplirsen ...

热点文章

更多